New hope for teens with painful skin condition
NCT ID NCT06768671
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 41 times
Summary
This study tests a drug called sonelokimab in 35 teens aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. The main goals are to see how the drug moves through the body and if it is safe. Researchers will also check if it helps reduce skin bumps and sores.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Site
North Little Rock, Arkansas, 72117, United States
-
Clinical Site
Stanford, California, 94304, United States
-
Clinical Site
Washington D.C., District of Columbia, 20010, United States
-
Clinical Site
Hollywood, Florida, 33201, United States
-
Clinical Site
Miami, Florida, 33136, United States
-
Clinical Site
Macon, Georgia, 31217, United States
-
Clinical Site
Sandy Springs, Georgia, 30328, United States
-
Clinical Site
Chicago, Illinois, 60611, United States
-
Clinical Site
Columbus, Indiana, 47201, United States
-
Clinical Site
Murray, Kentucky, 42071, United States
-
Clinical Site
Waterford, Michigan, 48328, United States
-
Clinical Site
Fargo, North Dakota, 58103, United States
-
Clinical Site
Charleston, South Carolina, 29425, United States
-
Clinical Site
Dallas, Texas, 75246, United States
-
Clinical Site
Dallas, Texas, 75390-8575, United States
-
Clinical Site
San Antonio, Texas, 78218, United States
-
Clinical Site
Norfolk, Virginia, 23502, United States
-
Clinical Site
Seattle, Washington, 98105, United States
Conditions
Explore the condition pages connected to this study.